Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by E Lespessailles
SAT0436 Durability of Apremilast Response in Patients With Psoriatic Arthritis: Long-Term (208-Week) Results From the Palace 1 Trial
Related publications
Longterm (52-Week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients With Psoriatic Arthritis
Journal of Rheumatology
Rheumatology
Allergy
Immunology
Therapeutic Benefit of Apremilast on Enthesitis and Dactylitis in Patients With Psoriatic Arthritis: A Pooled Analysis of the PALACE 1–3 Studies
RMD Open
Rheumatology
Allergy
Immunology
Work Productivity Improvement Associated With Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis Results of a Phase 3, Randomized, Controlled Trial
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pss13 - Budget Impact Analysis of Apremilast in Patients With Active Psoriatic Arthritis in Greece
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Long-Term Survival of Methotrexate in Psoriatic Arthritis
Reumatismo
Rheumatology
Cost Per Responder of Apremilast Versus Etanercept and Adalimumab in Patients With Active Psoriatic Arthritis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Improved Patient-Reported Outcomes in Patients With Psoriatic Arthritis Treated With Abatacept: Results From a Phase 3 Trial
Arthritis Research & Therapy
Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
Rheumatology and Therapy
Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Arthritis Care and Research
Rheumatology
